Association of body mass index with coronary plaque regression: 6-Month prospective study

Journal of Atherosclerosis and Thrombosis

Volumn 16, Issue 3, 2009, Pages 275-282

  Tani, Shigemasa ^a,b   Nagao, Ken ^a,b   Anazawa, Takeo ^a,b   Kawamata, Hirofumi ^a,b   Furuya, Shingo ^a,b   Takahashi, Hiroshi ^a,b   Iida, Kiyoshi ^a,b   Matsumoto, Michiaki ^a,b   Washio, Takahiko ^a,b   Kumabe, Narimichi ^a,b   Hirayama, Atsushi ^b  

^a NIHON UNIVERSITY   (Japan)

^b NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atherosclerosis; Body mass index; Obesity; Pravastatin

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; APOLIPOPROTEIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LONG ACTING DRUG; NITRATE; PRAVASTATIN; TICLOPIDINE;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; FEMALE; HUMAN; INTRAVASCULAR ULTRASOUND; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; REMISSION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 70350218742     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.E653     Document Type: Article

References (21)

1. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F, Lopez-Jimenez F: Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet, 2006; 368:666-678
2. Van Gaal LF, Mertens IL, De Block CE: Mechanisms linking obesity with cardiovascular disease. Nature, 2006; 444:875-880
3. Ohgaki S, Iida K, Yokoo T, Watanabe K, Kihara R, Suzuki H, Shimano H, Toyoshima H, Yamada N: Identification of ISG12b as a putative interferon-inducible adipocytokine which is highly expressed in white adipose tissue. J Atheroscler Thromb, 2007; 14:179-184
4. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalkwijk CG, Westendorp IC, Hofman A, Witteman JC: Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol, 1999; 19:1986-1991
5. Tani S, Watanabe I, Anazawa T, Kawamata H, Tachibana E, Furukawa K, Sato Y, Nagao K, Kanmatsuse K, Kushiro T; Surugadai Atherosclerosis Regression Investigators: Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol, 2005; 96:1089-1094
6. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004; 291:1071-1080
7. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA, 2006; 295:1556-1565
8. Okazaki S, Yokoyama T, Miyauchi K, Shimada K, Kurata T, Sato H, Daida H: Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study. Circulation, 2004; 110:1061-1068
9. Takashima H, Ozaki Y, Yasukawa T, Waseda K, Asai K, Wakita Y, Kuroda Y, Kosaka T, Kuhara Y, Ito T: Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque. Circ J, 2007; 71:1678-1684
10. Tani S, Nagao K, Anazawa T, Kawamata H, Iida K, Matsumoto M, Sato Y, Hirayama A: Association of circulating leukocyte count with coronary atherosclerosis regression after pravastatin treatment. Atherosclerosis, 2008; 198:360-365
11. Smith SC Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH, Jacobs A, Jones D, Krauss RM, Mosca L, Ockene I, Pasternak RC, Pearson T, Pfeffer MA, Starke RD, Taubert KA: AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update. A statement for healthcare protessionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol, 2001; 38:1581-1583
12. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M: Treatment - therapeutic lifestyle modification. J Atheroscler Thromb, 2008; 15:109-115
13. Examination Committee of Criteria for 'Obesity Disease' in Japan; Japan Society for the Study of Obesity: New criteria for 'obesity disease' in Japan. Circ J, 2002; 66:987-992
14. Matsuzawa Y: White adipose tissue and cardiovascular disease. Best Pract Res Clin Endocrinol Metab, 2005; 19:637-647
15. Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Hazen SL, Ntanios F, Wun CC, Nissen SE: Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). Am J Cardiol, 2006; 97:1553-1557
16. Obesity. Preventing and managing the global epidemic: Report of a WHO Consultation on Obesity, Geneva. 3. Global prevalence and secular trends in obesity. Geneve: World health Organization, 1997
17. Yoshiike N, Matsumura Y, Zaman MM, Yamaguchi M: Descriptive epidemiology of body mass index in Japanese adults in a representative sample from the National Nutrition Survey 1990-1994. Int J Obes Relat Metab Disord, 1998; 22:684-687
18. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet, 1996; 348(9038):1339-1342
19. Yamamoto A, Horibe H, Mabuchi H, Kita T, Matsuzawa Y, Saito Y, Nakaya N, Fujioka T, Tenba H, Kawaguchi A, Nakamura H, Goto Y: Analysis of serum lipid levels in Japanese men and women according to body mass index. Increase in risk of atherosclerosis in postmenopausal women. Research Group on Serum Lipid Survey 1990 in Japan. Atherosclerosis, 1999; 143:55-73
20. Nakamura H, Arakawa K, Itakura H, Kitabatake A, Goto Y, Toyota T, Nakaya N, Nishimoto S, Muranaka M, Yamamoto A, Mizuno K, Ohashi Y; MEGA Study Group: Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet, 2006; 368:1155-1163
21. Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Despres JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM; STRADIVARIUS Investigators: Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA, 2008; 299:1547-1560